University College London is raising funds for the world’s largest brain imaging study on psychedelics, aka Project UNITy.
In the first phase of the study, 150 people will receive three brain scans: one while watching a movie, one while dosed with DMT or a placebo, and another while watching a movie post-DMT trip or placebo.
Then, researchers will use an app to track participants’ changes in wellbeing for one year.
The study will reveal which specific brain networks are altered on DMT (such as those related to vision, memory, or language), as well as which networks are linked to positive changes in wellbeing.
If successful, a second phase of the study will be conducted to see if DMT can reduce alcohol consumption and “reactivate” memory networks in hazardous drinkers.
Those who make a contribution to the study can receive goodies like trippy artwork, event tickets, and even a dinner with the scientists.
Vernon, British Columbia, June 1, 2022 – Doseology Sciences Inc. (CSE: MOOD) (FSE: VU7) (OTC: DOSEF) (“Doseology” or the “Company”), a life sciences company focused on mental health and wellness, is pleased to announce that its common shares (the “Shares”) were approved for trading on the OTC Pink Open Market in the United States under the symbol “DOSEF”. The Shares will continue to trade on the Canadian Securities Exchange under the symbol “MOOD” and on the Frankfurt Stock Exchange under the symbol “VU7”. The Company has also applied to uplist its Shares from the Pink Open Market to the OTCQB Market in the United States.
The Company is pleased to announce that the Shares have been approved for eligibility for book-entry and depository services through the Depository Trust Company (“DTC”) in the United States, which will facilitate electronic clearing and settlement of transfers of the Shares.
DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered “DTC eligible”. With an accelerated settlement period and reduced costs for investors and brokers, DTC eligibility is expected to simplify the process of trading and enhance liquidity of the Company’s shares in the United States.
Ralph Olson, CEO of the Company, stated: “We are pleased to have obtained our dual USA listing and DTC eligibility. This eligibility will simplify the process of trading shares in the USA, which will be beneficial to Doseology and our shareholders. With DTC eligibility, the increased accessibility and visibility is expected to attract greater investment and trading liquidity from American investors as our shares will be available to a broader range of investors as we continue to expand our business.”
On Behalf of the Board of Directors
Ralph Olson Chief Executive Officer Doseology Sciences Inc
About OTC Pink Open Market
The Pink Open Market, operated by OTC Markets Group Inc., provides brokers with a regulated platform for transparent trading and best execution. Brokers quote a wide spectrum of companies on this market, including foreign companies that limit their disclosure in the U.S., penny stocks and shells. To be eligible for quotation on the Pink Market, companies must comply with the requirements of Securities Exchange Act Rule 15c2-11, including providing current information to the investing public.
Doseology Sciences Inc. is building a progressive brand focused on mental health and wellness through cultivation, extraction and innovative nutraceutical and pharmaceutical products. Doseology aims to make a meaningful impact on the mental health pandemic by utilizing and developing psychedelic and non-psychedelic compounds within the functional fungi and plant-derived drug markets. With a vertically integrated approach, Doseology intends to process and distribute products at its facilities in Vernon, British Columbia, in accordance with applicable laws to ensure safe and high-quality production. Doseology’s medicinal mushroom products, including tinctures, powders and supplements, are available on doseology.com.
This press release contains statements that constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company’s prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. For more information, investors should review the Company’s filings which are available on SEDAR.
No securities regulatory authority has either approved or disapproved of the contents of this press release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration, or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
British Columbia received a 3-year exemption to decriminalize small amounts of opioids, cocaine, methamphetamine and MDMA.
“By removing the fear and shame of drug use, we will be able to remove barriers that prevent people from accessing harm reduction services and treatment programs,” says provincial health officer Dr. Bonnie Henry.
While it seems like a step in the right direct, the legislation is being criticized because it only allows possession of 2.5 grams of the drugs and it won’t be effective until January 31 of 2023.
Patent claims cover methods of administering psilocybin and psilocin to patients having reduced monoamine oxidase A activity
New patent expires in 2041
Given implications to patient safety, Lennham’s discoveries are likely to cover information in the label of any future psilocybin- or psilocin-based product or structurally related compounds
May 31, 2022 10:03 AM Eastern Daylight Time
CONCORD, Mass.–(BUSINESS WIRE)–Lennham Pharmaceuticals, a start-up focused on the creative use of deuterium chemistry to improve the metabolic and pharmacological profile of existing compounds, today announced that the United States Patent & Trademark Office (USPTO) issued U.S. Patent No. 11,344,564 with an expiration date of December 2041. This patent covers methods of treating neurological or psychiatric disorders in patients having reduced monoamine oxidase A (MAO-A) activity by administering a below-normal dose of psilocybin or psilocin.
“Lennham has discovered that certain patient populations have traits that may affect the metabolism and, consequently, the pharmacological effects of psilocybin and its active metabolite, psilocin, at the site of action in the CNS”Tweet this
“Lennham has discovered that certain patient populations have traits that may affect the metabolism and, consequently, the pharmacological effects of psilocybin and its active metabolite, psilocin, at the site of action in the CNS,” said Bradford C. Sippy, Founder of Lennham. “Although glucoronidation is psilocin’s primary metabolic route systemically, metabolism by MAO-A plays a much greater role at the site of action. The use of psilocybin or psilocin in patients having an MAO-A deficiency requires a new approach to administration of those products. Our newly issued patent covers methods of using psilocybin and psilocin in these patient populations, which we believe will be incorporated into the eventual labeling for any psilocybin- or psilocin-based product.”
About Psilocybin Psilocybin is a well-known, naturally occurring chemical in certain mushrooms that is known to produce hallucinogenic (psychedelic) effects in humans when consumed. It is currently being evaluated as a potential treatment for treatment-resistant depression1 and major depressive disorder, among other diseases and conditions.
About Lennham Pharmaceuticals, Inc. Lennham is a privately held, life sciences company focused on the creative application of deuterium chemistry to highly utilized and well-characterized compounds. Founded in 2019, Lennham’s unique approach to deuteration has enabled it to rapidly develop a pipeline of product candidates, including deuterium-enriched forms of psilocybin, caffeine, and testosterone.
CHICAGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE) — Wesana Health Holdings Inc.(“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, has today announced its first quarter 2022 financial results.
Q1 2022 Highlights
Delivered findings indicating psilocybin potentiates impact of anti-depressant
Received positive feedback from pre-Investigational New Drug (“IND”) meeting with U.S. Food and Drug Administration (“FDA”) on SANA-013
Announced positive findings from Animal Study on Novel Depression Treatment Protocol Combining Psilocybin and Cannabidiol
Record Q1 2022 operating results at Wesana Clinics
Opening of third Wesana Clinic in May 2022
Launched strategic Review of Care Delivery Assets
Select Consolidated Financial Information
The following table sets forth selected financial information derived from the Company’s unaudited interim combined and consolidated financial statements and notes thereto for the three-months ended March 31, 2022. The following information should be read in conjunction with the financial statements and the accompanying management’s discussion and analysis (“MD&A”), which are available on the Company’s website at www.wesanahealth.com and under the Company’s SEDAR profile at www.sedar.com.
For the three months ended ($USD)
Mar 31, 2022
Dec 31, 2021
Weighted Average Shares Outstanding
Fully Diluted Shares Outstanding (as converted*)
*The number is presented assuming all of the Company’s outstanding Proportionate Subordinate Voting Shares and Super Voting Shares as at March 31, 2022 are converted into Subordinate Voting Shares in accordance with their terms and all of the Company’s other outstanding convertible, exchangeable and exercisable securities as at March 31, 2022 are converted, exchanged or exercised in accordance with their terms.
Business Updates and Highlights
“We are delighted with our progress on SANA-013 and our accelerated pathway toward development,” said Wesana CEO and Chairman, Daniel Carcillo. “Our shift in focus to our drug development program will be instrumental in working toward the Company’s goal of FDA approval for SANA-013.”
New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant
On March 22, 2022, Wesana delivered data from an animal study, conducted by an independent global laboratory services provider in a validated model of depression. Results of the study showed that administration of imipramine given three weeks following a psilocybin loading dose provided an additional 39% improvement in depressive behaviors from that of psilocybin loading dose alone. Furthermore, a second administration of imipramine given four weeks after a psilocybin loading dose provided an even greater reduction (45%) in depressive behaviors.
Positive Feedback from Pre-IND Meeting with FDA on SANA-013
On March 14, 2022, Wesana reported it received a full written response from the FDA regarding their pre-IND meeting for the novel therapy and proprietary protocol of SANA-013 for the treatment of Traumatic Brain Injury (“TBI”) related MDD.
The Company received positive written responses from the FDA on March 11th outlining the requirements to open the IND and commence clinical studies for SANA-013. The written response provides a path to agreements on IND-enabling studies and validates the team’s recent effort and accomplishments. The FDA response also provided important insights pertaining to advancing SANA-013 as a potential treatment for TBI-related MDD. Wesana intends to initiate its in-human clinical study program in late 2022.
Positive Findings from Animal Study on Novel Depression Treatment Protocol Combining Psilocybin and Cannabidiol
On January 18, 2022, Wesana shared positive results of an animal study on a novel depression treatment protocol. Combining psilocybin and cannabidiol, the animal study, conducted by an independent global laboratory services provider, demonstrated considerable and sustained improvement in depressive behaviors.
Wesana’s novel and proprietary depression treatment protocol includes a single high dose of psilocybin followed by a maintenance regimen of a microdose of psilocybin combined with cannabidiol. In a validated pre-clinical animal model of depression, the maintenance regimen demonstrated up to 64% further improvement than those observed with a single high dose of psilocybin alone.
Furthermore, the maintenance regimen provided a sustained antidepressant effect after the single high dose of psilocybin. Wesana’s proprietary treatment protocol is currently being evaluated for the treatment of multiple mental health conditions including major depressive disorder associated with traumatic brain injury.
Strategic Rationale for Clinics and Other Care Delivery Asset Review:
Feedback from the FDA validates the Company’s strategic plan for simplification and growth. Given the clarity provided by FDA in the pre-IND meeting, and the Company’s increased focus on drug development, Wesana has commenced a strategic review of the Company’s assets with a focus on reviewing Wesana’s care delivery division. The Company is reviewing strategic alternatives including, but not limited to, a sale of all the assets under the care delivery division, including:
Wesana Clinics – a network of psychiatrist-led mental health clinics focused on serving the community through the delivery of personalized innovative psychiatric care, inclusive of ketamine therapy, medication management, psychotherapy, cognitive testing, and pharmacogenetic testing.
Wesana Solutions – a medical-grade clinical SaaS platform focused on improving mental healthcare through facilitating access to leading edge clinical protocols and tracking their efficacy. In concert with EMRs and practice management systems, Wesana Solutions is intended to be used in clinics delivering psychedelics and related therapies, targeting the developing international psychiatric clinic and research market.
PsyTech Connect – a leading community for the clinical use of psychedelics with over 8,000 actively engaged professionals.
Wesana today announced that, as part of a Board of Directors transition, Chad Bronstein has tendered his resignation as Executive Chairman, effective immediately, to pursue other professional opportunities. In connection with Mr. Bronstein’s resignation, the Company is pleased to announce the Company’s Board of Directors’ appointment of Daniel Carcillo as Chairman.
“I am incredibly proud of the Company that we have built and the progress we have made to date,” commented Mr. Bronstein, “and I look forward to seeing the continued evolution of Wesana under Daniel’s leadership as the Company moves towards advancing its clinical development program and human clinical trials in the coming months later this year.”
Bronstein was instrumental in the founding of the Company as well as in its first years of growth. His commitment to Wesana over the past two years helped the Company go-public on the Canadian Securities Exchange and raise $17 million in capital, to initiate the FDA drug development and approval process.
“On behalf of everyone at Wesana, I would like to express my heartfelt gratitude to Chad for his support and guidance through Wesana’s early growth. Chad was a visionary leader who provided excellent stewardship as we navigated the going-public and related capital raise process. As we position ourselves for our next phase of growth, we will continue on the path Chad and I set to develop and deliver life-changing medicine to those in need,” said Daniel Carcillo, Wesana’s Founder and CEO.
About Wesana Health
Wesana Health helps people transcend barriers in mental health and performance. We innovate in care development through our therapies and patent-pending protocols, and in care delivery through activating a new multidisciplinary, technology-supported clinical model. Learn more at www.wesanahealth.com.
Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” within the meaning of applicable securities laws with respect to the Company, including, but not limited to: the initiation of Phase 1 clinical trials in late 2022, exploration of MDD as the lead indication for SANA-013, and any other statement that may predict, forecast, indicate or imply future plans, intentions, levels of activity, results, financial position, operational or financial performance or achievements. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “will”, “projects”, or “believes” or variations (including negative variations) of such words and phrases, or statements that certain actions, events, results or conditions “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Except for statements of historical fact, information contained herein constitutes forward-looking information. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made.
Certain assumptions that influence successfully initiating its clinical development program in late 2022 include: (i) third parties who assisted the Company with the pre-IND submissions will continue to satisfy deadlines on deliverables within anticipated timeframes; (ii) the pre-IND guidance will continue to support that a drug development plan and future clinical trials are going to be acceptable to the FDA; (iii) the Company and its consultants can efficiently and timely address any additional correspondence, submission of additional materials or information pursuant to any ongoing requests as they may arise during the course of their review following the filing of submissions; (iv) additional pre-clinical studies will be commenced and completed on a timely basis and results will be supportive and as anticipated; (v) the Company’s pre-clinical studies (animal pharmacology and toxicology testing) generate data and analyses to support an FDA decision that it is safe to proceed with human trials of the Company’s formulation; and (vi) the Company is able to maintain a GMP supply source necessary to conduct in-human clinical trials.
Certain assumptions that influence successfully expanding the lead indication for SANA-013 to MDD include all of the assumptions in the above and (i) the board of directors of the Company (the “Board”) continues to determine and approve, based on the readiness of the overall research and development plan, capital resources and internal procedures of the Company, the expansion of the lead indication to MDD; (ii) the Company’s current capital will be sufficient for developing the updated IND submission package and updated IND enabling studies; (iii) the broadened indication and the future clinical trials are going to be acceptable to the FDA; (iv) the Company and its consultants can efficiently and timely address any additional correspondence, submission of additional materials or information pursuant to any ongoing requests as they may arise resulted from the broaden indication; and (v) additional pre-clinical studies required for MDD will be commenced and completed on a timely basis and results will be supportive and as anticipated.
Any patent efforts of the Company remain at the application stage and there is no assurance that the Company will file additional patent applications or in what jurisdictions they may be filed, if any. Furthermore, while the PCT application has been filed, there is no assurance that a patent(s) will be granted or will be granted in a form that will be sufficient to protect the Company’s proprietary therapies or protocols or enable it to gain or keep any competitive advantage that it may have.
Although management believes that the anticipated future results, performance or achievements expressed or implied by the forward-looking statements are based upon reasonable assumptions and expectations, the reader should not place undue reliance on forward-looking statements because they involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from anticipated future results, performance or achievements expressed or implied by such forward-looking statements. Certain risk factors include but are not limited to there being no assurance as to the Company’s ability to continue as a going concern; there being no assurance that the strategic review of the Company’s care and delivery division will result in any viable alternatives or a definitive transaction; there being no assurance that the net proceeds of the recently completed private placement will be used as currently contemplated by the Company, the allocation and use of which is at the discretion of the Company, or that the Company will achieve the results from the use of such proceeds as currently targeted; the detrimental impact of future losses and negative cash flow from operations; requirements for additional capital; lack of product or service revenue; research and development of drugs targeting the central nervous system being particularly difficult; failure to comply with health and data protection laws and regulations; delays in pre-clinical and clinical testing resulting in delays in commercializing; inability to file investigational new drug applications or clinical trial applications to commence clinical trials in a timely manner; difficulty enrolling patients in clinical trials; competition from other biotechnology and pharmaceutical companies; violations of laws and regulations resulting in repercussions; psychedelic inspired drugs possibly never being approved as medicines; regulatory or political change; reliance on third parties to plan, conduct and monitor preclinical studies and clinical trials; requirements of commercial scale and quality manufactured drug supply; negative results from pre-clinical and clinical trials or studies of others; unfavourable publicity or consumer perception; not achieving publicly announced milestones; reliance on the capabilities and experience of key executives and scientists; disruptions due to acquisitions or collaborations; risk of product liability claims; COVID-19; litigation; conflicts of interest; limited operating history; general economic, market and business conditions and other risk factors including those found in the MD&A and the Company’s annual information form dated September 3, 2021 filed on the Company’s profile on SEDAR at www.sedar.com and discussed in the Company’s other public filings available on SEDAR.
Forward-looking information is provided and made as of the date of this news release and the Company does not undertake any obligation to revise or update any forward-looking information other than as required by applicable law.
Record high quarterly revenue of $3,227,352, +32% over the previous quarter
Growth driven by Arizona acquisition, expanding clinic network to eight total locations
Numinus to acquire Novamind, creating a preeminent North American platform, spanning 13 wellness clinics, four research sites and one bioanalytical laboratory
TORONTO, ON / May 31, 2022 / Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, reported its financial results for the three and nine months ended March 31, 2022 (“Fiscal Q3 2022”). All results are reported under International Financial Reporting Standards (“IFRS”) and in Canadian dollars, unless otherwise specified.
Novamind CEO, Yaron Conforti, commented, “Once again, we’re pleased to report record-high revenue this quarter. Growth was driven by our recent expansion to Arizona in addition to the continued progress of our Utah operations. With the anticipated shareholder approval of the acquisition of Novamind by Numinus in June, the Company is well-positioned to continue this record growth in pursuit of its mission to responsibly reintroduce psychedelic therapy to mental healthcare.”
Fiscal Q3 2022 Operating Highlights and Subsequent Events
The Company entered into a definitive arrangement agreement (the “Arrangement”) pursuant to which Numinus Wellness (“Numinus”), will acquire Novamind in an all-share transaction
Pending shareholder approval, holders of Novamind common shares (“Novamind Shareholders”) will receive 0.84 of a common share of Numinus for each Novamind share held
The Arrangement values Novamind at $26.2 million on a fully diluted in-the-money basis, representing a premium of 51% to Novamind’s 20-day volume-weighted average price on the Canadian Securities Exchange as of April 8, 2022
A special meeting of the Company’s shareholders will be held on June 8, 2022, to approve the proposed acquisition of Novamind by Numinus
Closed the acquisition of Arizona-based Foundations for Change, Inc., a mental health practice specialized in ketamine-assisted psychotherapy
Opened the Company’s eighth integrative psychiatry clinic, located in Phoenix, Arizona
Launched Groups by Novamind, an expansion of the Company’s clinical care model focused on increasing patient access to mental health treatments
Novamind’s strategic partner, Bienstar Wellness Corp., signed a letter of intent to acquire BRC Saude Mental E Terapias Assistidas Ltda., a leader in specialized ibogaine treatments for substance use disorder based in Sao Paolo, Brazil
Contracted to provide clinical research services for the following clinical trials:
A phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder in adults, sponsored by MindMed
A phase II clinical trial investigating psilocybin for major depressive disorder, sponsored by the Usona Institute
A phase II clinical trial investigating ketamine-assisted psychotherapy for adults with life-threatening illnesses, sponsored by the Ketamine Research Foundation
A phase I clinical trial investigating the safety and efficacy of ketamine-assisted psychotherapy combined with Mindfulness-Oriented Recovery Enhancement therapy for the treatment of adults with opioid use disorder
A phase II clinical trial investigating an antidepressant medication for adults with major depressive disorder and PTSD, sponsored by Alto Neuroscience
A phase II randomized clinical study for the acute treatment of social anxiety disorder, sponsored by Bionomics
Fiscal Q3 2022 Financial Highlights
Total revenue $3,227,352, +32% over the previous quarter
Total working capital of $3,928,642 to fund operations
Closed a $5,000,000 private placement with an institutional investor
The following table presents selected financial information from Novamind’s reviewed condensed interim financial statements for the three and nine months ended March 31, 2022. The following information should be read in conjunction with the financial statements and management’s discussion and analysis, which are available under Novamind’s SEDAR profile at www.sedar.com.
Supplemental Disclosure for Circular Novamind confirms that the management information circular dated May 6, 2022 (the “Circular”), form of proxy and other materials with respect to the Company’s Arrangement with Numinus have been mailed to Novamind Shareholders of record as of May 2, 2022.
The Company wishes to provide the following additional disclosure to supplement and amend the disclosure in the Circular. Capitalized terms not otherwise defined below shall have the meanings ascribed to such terms in the Circular.
The Company confirms that the Novamind Board, other than Yaron Conforti, who abstained from voting on the Arrangement, has determined that the Arrangement is fair to Novamind Shareholders, that the Arrangement is in the best interests of Novamind and unanimously recommends that Novamind Shareholders vote FOR the Arrangement Resolution. Mr. Conforti abstained from voting on the Arrangement on the basis that he will receive a change of control payment in connection with the Arrangement, as described in more detail in the Circular under “The Arrangement – Interests of Certain Persons in the Arrangement – Change in Control Payment”.
The Company also wishes to advise that the definition of Supporting Shareholders referenced on pages 17 and 24 of the Circular misstated that Support Agreements were entered into with directors and officers of Novamind and “a certain Novamind Shareholder”. The Company clarifies that only certain directors and officers of Novamind entered into Support Agreements, and no non-director or officer Novamind Shareholders entered into a Support Agreement. Copies of the Support Agreements have been uploaded to the Company’s SEDAR profile.
About Novamind Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.
Contact Information Novamind Yaron Conforti, CEO and Director Telephone: +1 (647) 953 9512
Forward-Looking Statements This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.
Shrooms are known to cause nausea, so you wouldn’t expect them to help with digestive issues.
However, the Toronto-based startup Dyscovry Science Ltd. is developing a synthetic psilocybin formulation to target irritable bowel syndrome (IBS). Psilocybin’s anti-inflammatory effect may help with the disorder.
The preliminary research must be promising because Silo Wellness (SILO) just entered into an agreement to acquire 100% of Dyscovry Science.
Cybin (CYBN), PharmAla Biotech (MDMA), PharmaTher (PHRM), and 9 other companies joined forces to create Psychedelics Canada – the first ever national trade association for legal psychedelics companies.
The association will speak on behalf of the psychedelics industry to government, the press, and the public to advance psychedelic research and policy change.
Halucenex to receive recently harvested first batch of psilocybe cubensis
VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with Halucenex Life Sciences Inc. (“Halucenex”), a wholly owned subsidiary of Creso Pharma of Australia (ASX: CPH). Halucenex is based in Windsor, Nova Scotia and is a life sciences company focused on researching novel psychedelic compounds, developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets, and conducting clinical trials on the medical benefits of psychedelic medicine.
Additionally, Optimi wishes to confirm that the supply agreement pertains to the entirety of the Company’s recently harvested first batch of psilocybe cubensis mushrooms at its Princeton, British Columbia facility. The mushrooms will be supplied to Halucenex in the form of whole, dried mushroom fruiting bodies.
“This first supply agreement, coming so soon after our first complete cultivation cycle, is a powerful affirmation of our decision to pursue the development of natural, GMP psilocybin,” said Bill Ciprick, CEO of Optimi. “From this initial proof-of-concept batch, our cultivation team will continue to scale our operations to meet the demands of the sector, domestically and internationally with licensed entities and for individual patients within Canada according to the terms of the Special Access Program.”
Halucenex CEO, Bill Fleming, says the agreement with Optimi is one both companies will benefit from.
“We’re very excited to be moving forward on this supply agreement with the team at Optimi Health,” said Fleming. “Among our top priorities in the development of a psychedelic-assisted psychotherapeutic model for conditions such as anxiety and post-traumatic stress disorder has been to secure a safe, consistent supply of GMP psilocybin.”
Authorized parties interested in purchasing Optimi psilocybin and functional mushroom products should send an email to firstname.lastname@example.org where a member of the sales team will respond within 24 hours.
ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)
Optimi Health Inc. is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets. Built with the purpose to produce scalable, natural mushroom formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe, natural GMP grade psilocybin across the world. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional and psychedelic mushroom products at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.
To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of psilocybin and psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also been granted a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of psilocybin and psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.
Optimi was recently granted an amendment to its Dealer’s Licence by Health Canada, allowing the Company to possess a quota of up to 5000kg of dried psilocybin mushrooms – the equivalent of 10kg of psilocybin – and 100g of psilocin.
Halucenex operates a 6000 sq ft medical facility in Windsor, Nova Scotia with six treatment rooms and a secure laboratory dedicated to performing psychedelic-assisted psychotherapy and clinical research. Halucenex intends to maintain control over all aspects of the product development process – mycological research, extraction technology, and synthetic formulation as well as drug delivery technologies, psychedelic-assisted psychotherapy and regulatory affairs.
Clinically, Halucenex is focused on researching psilocybin, psilocybin-derivatives, and other psychedelic medicine for the purposes of treating clients suffering from PTSD and anxiety using its comprehensive psilocybin-assisted psychotherapy treatment model. Halucenex is committed to advancing the science around the use of psilocybin in psychedelic-assisted psychotherapy by:
For more information or to request an interview, please contact:
Michael Kydd Media & Stakeholder Relations Advisor Email: email@example.com Phone: +1 (902) 880 6121
Sara Reed, licensed marriage and family therapist, tried MDMA therapy as part of MAPS’ training program. Her experience deepened her understanding of herself and helped her process the loss of her grandmother.
“As the medicine and the music carried me away, my grandmother appeared. Tears flowed down my face and joy filled my heart. It had been years since I had felt her presence like this. Seeing her in this bright, liberating light was an important part of my grieving process.
She took me to a place I knew existed but had never seen. I traveled to what felt like the essence of the universe, a space of Divinity, a place where I belonged. The vision revealed my presence within this enormous Whole—a place that had no beginning or end, where there is no distinction or separation from love. I call that place home. And for the first time in my adult life, I felt freedom. Me, a young Black woman. Free. Human.”
The experience also made Sara realize that the psychedelics industry needs to prioritize culturally sensitive care to make treatments safer and more accessible for BIPOC communities.